293 Aufrufe 293 0 Kommentare 0 Kommentare

    HYTN Announces Marketing Program

    VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a company specializing in the pharmaceutical development and production of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has engaged bullVestor Medien GmbH (“bullVestor”) (address: Gutenhofen 4, 4300, St. Valentin, Austria email: kontakt@bullvestor.at) to provide marketing services for an anticipated period of 6 months, or until budget exhaustion, commencing on November 15th, 2024, and provided that the term of the marketing services may be extended or shortened at the discretion of management.

    bullVestor is arm’s length to the Company, and the marketing services will include the creation of content, ad groups and display ads, as well as keyword optimization, project management, and media distribution, with an objective to generally bring attention to the business of the Company. The Company will pay €300,000 to bullVestor for the marketing services. The Company will not issue any securities to bullVestor in compensation for the marketing services. To the Company's knowledge, neither bullVestor, nor its directors or officers, own any securities of the Company.

    About HYTN Innovations Inc.

    HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and Psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.

    For more information contact:

    Elliot McKerr
    Chief Executive Officer
    1.866.590.9289

    HYTN Investor Relations:
    1.866.590.9289
    investments@hytn.life

    The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.

    Certain information contained herein may constitute forward-looking statements. These statements involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements. Any statements that are not statements of historical fact are deemed to be forward-looking statements. Any forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    HYTN Announces Marketing Program VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) - HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a company specializing in the pharmaceutical development and production of psychoactive and …